| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Princeton, N.J., November 12, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has c... |
| 12 Nov 2026 | 10-Q |
| 05 Nov 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 10,328 shares ($18.5K) · Bought 5,027 shares ($9.06K) · Bought 3,087 shares ($5.48K) |
| 26 Oct 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 21,390 shares ($41.2K) · Bought 66,411 shares ($117K) |
| 21 Oct 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 4,256 shares ($8K) |
| 16 Oct 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 11,233 shares ($21.7K) · Bought 23,485 shares ($45.7K) · Bought 36,347 shares ($68.8K) |
| 13 Oct 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 2,077 shares ($4.19K) · Bought 5,340 shares ($10.9K) · Bought 7,215 shares ($14.6K) |
| 05 Oct 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 38,796 shares ($79K) · Bought 20,000 shares ($41.4K) · Bought 1,694 shares ($3.49K) |
| 01 Oct 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 7,849 shares ($16.4K) |
| 01 Oct 2026 |
Form 4/A: Opaleye Management Inc., 10% owner
Bought 9,771 shares ($20.5K) · Bought 5,318 shares ($11.2K) |
| 23 Sep 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 9,771 shares ($20.5K) · Bought 5,318 shares ($11.2K) |
| 21 Sep 2026 |
Form 4: Neugeboren Edward, Director
Granted 12,200 Stock Option (Right to Buy) |
| 21 Sep 2026 |
Form 4: Davis A Brian, Director
Granted 0 Stock Option (Right to Buy) |
| 21 Sep 2026 |
Form 4: Kavuru Vimal, Director
Granted 12,200 Stock Option (Right to Buy) |
| 21 Sep 2026 |
Form 4: Kottayil George, Director
Granted 12,200 Stock Option (Right to Buy) |
| 18 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 17, 2026, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended,... |
| 10 Sep 2026 |
Form 4: Opaleye Management Inc., 10% owner
Bought 9,393 shares ($19.7K) · Bought 5,836 shares ($12.2K) |
| 10 Sep 2026 |
Form 4: Kohli Prashant, Director
Bought 100,000 shares ($214K) |
Loading...